BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide

Luis Sanchez-Perez, Bryan D. Choi, Elizabeth A. Reap, Elias J. Sayour, Pamela Norberg, Robert J. Schmittling, Gerald E. Archer, James E. Herndon, Duane A. Mitchell, Amy B. Heimberger, Darell D. Bigner, John H. Sampson*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

B lymphocyte stimulator (BLyS) is a cytokine involved in differentiation and survival of follicular B cells along with humoral response potentiation. Lymphopenia is known to precipitate dramatic elevation in serum BLyS; however, the use of this effect to enhance humoral responses following vaccination has not been evaluated. We evaluated BLyS serum levels and antigen-specific antibody titers in 8 patients undergoing therapeutic temozolomide (TMZ)-induced lymphopenia, with concomitant vaccine against a tumor-specific mutation in the epidermal growth factor receptor (EGFRvIII). Our studies demonstrate that TMZ-induced lymphopenia corresponded with spikes in serum BLyS that directly preceded the induction of anti-EGFRvIII antigen-specific antibody titers, in some cases as high as 1:2,000,000. Our data are the first clinical observation of BLyS serum elevation and greatly enhanced humoral immune responses as a consequence of chemotherapy-induced lymphopenia. These observations should be considered for the development of future vaccination strategies in the setting of malignancy.

Original languageEnglish (US)
Pages (from-to)983-987
Number of pages5
JournalCancer Immunology, Immunotherapy
Volume62
Issue number6
DOIs
StatePublished - Jun 2013
Externally publishedYes

Keywords

  • BAFF
  • BLyS
  • Immunotherapy
  • Lymphopenia
  • Temozolomide
  • Vaccines

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide'. Together they form a unique fingerprint.

Cite this